EXPOSED
The bench half of the job — culturing, plating, staining, PCR setup, colony counts, microscopy reads — is physical and still needs hands, but it is exactly the work high-throughput liquid handlers and automated imaging platforms have been eating for a decade, while AI handles the literature reviews, sequence annotation, statistical write-ups, and protocol drafting. The modal worker here is a research or industrial/QC microbiologist, not a clinical lab director; only the clinical and CLIA-regulated tier carries certification requirements that function as a shield. What persists is experimental design under ambiguity, contamination and out-of-spec investigations, and owning the call on whether a lot, a strain, or a result is trustworthy.
Roughly flat across the period, with year-to-year wobble.
Median pay $75,650 → $87,990 -7.0% in real terms
This line is counted by the Bureau of Labor Statistics — the one figure on this page that isn't a judgement of ours. Headcount moves on demand, offshoring, demographics and the business cycle, and automation is one term among several, often not the loudest.
So a falling line is not evidence that AI did it, and a rising one is not evidence that it won't. Both happen in this register: some occupations resist automation and shrink anyway, others are highly automatable and keep growing. The marked year is 2020.
BLS projection, 2024–2034
+4.1% 20,700 → 21,600 on the projections basis
Growing, and only partly exposed
The BLS expects +4.1% more of these jobs by 2034, and at 46/100 the work is only partly exposed — some tasks are automatable, the core of the job is not. Nothing here is in tension.
Different clocks. The score is what current AI could do to this work today. The projection is how many of these jobs will exist in 2034. Everything between the two — how fast employers actually adopt, whether demand grows in the meantime — is why they can point opposite ways without either being wrong.
~1,700 openings a year on average, including replacing people who leave.
ScientistCytologistVirologistMicroscopistBacteriologistMicrobiologistResearch AssociateResearch SpecialistMedical TechnologistMicrobiology AnalystElectron MicroscopistMedical MicrobiologistMicrobiology ScientistClinical MicrobiologistMicrobiological AnalystMicrobiology SpecialistResearch MicrobiologistPublic Health MicrobiologistPharmaceutical MicrobiologistQuality Control Microbiologist (QC Microbiologist)Medical Lab Scientist (Medical Laboratory Scientist)QA Microbiologist (Quality Assurance Microbiologist)Clinical Laboratory Scientist (Clinical Lab Scientist)Quality Control Microbiology Analyst (QC Microbiology Analyst)
Holding it up: embodiment . Weakest point: trust premium .
Mixed — a routine tier and a judgment tier Streak plates, broth dilutions, gram stains, qPCR plate setup and colony enumeration are all now catalogue items on Hamilton/Tecan decks and automated colony counters, and 16S/WGS annotation plus draft methods sections are near-solved — an 11 rather than a 15 because designing a challenge study, troubleshooting why an anaerobe won't grow, or reading an atypical Gram morphology still needs someone at the bench who has seen it before.
Some physical or field component You are in BSL-2 containment handling live cultures, autoclaving, working a biosafety cabinet, swabbing environmental monitoring sites on a production floor — real physical work, but in a controlled, mapped room with fixed instruments, which is why this sits at 12 and not with field ecologists or line mechanics working in weather and rubble.
Certification preferred, not legally required Most microbiologists hold a BS or PhD and no licence at all; ASCP/ASM certification and CLIA high-complexity testing personnel status apply only to the clinical subset, and even there the CLIA laboratory director signs off — a 6 reflects credential preference and QC training records, not a personal signature that carries statutory exposure.
Meaningful discretion Deciding whether a sterility failure is a true positive or lab contamination, whether a lot is released or destroyed, whether an OOS root cause investigation closes — those are consequential calls made under real ambiguity, but they run through documented SOPs, USP/ISO methods and a QA approval chain, so you propose the conclusion rather than being the last word, which puts this at 11 not 16.
The verdict above describes this occupation as a whole. Almost nobody does the typical version of a job — tick what's actually in your week and see how your own mix sits.
Your task mix speaks to task resistance (11/20 here) — how much of the day's work current AI already does. That is the dimension the boxes above are about.
It cannot move the other three. Liability shield (6/20) is whether the law requires a licensed human to sign. Trust premium (6/20) is whether buyers specifically pay for a person. Judgment and accountability (11/20) is whether the role exists to own consequential calls. Those are facts about the occupation's standing, not about which tasks are in your week — a paralegal who does only trial exhibits still holds no licence. Together they are 23 of this occupation's 46 points (50%).
Embodiment (12/20) is also a property of the work rather than the worker, but we don't tag individual tasks as physical or not, so the picker can't tell you anything about it. That's a limit of this tool, not a claim.
Did we get the list right? Tell us what's missing — the tasks are written from the outside, and you're reading this from the inside.
The moves above are yours to make. This is the other half: what would have to change in the world for the occupation itself to score higher. None of it is in any one person's gift, but it is where the floor actually comes from. Scores here are not a one-way ratchet. Only two of the five dimensions — task resistance and embodiment — track what machines can do. The other three track law, what buyers will pay for, and who is answerable, and those move in both directions, often in response to the same pressure AI creates. If every lever below landed, this occupation would score around 63/100, still EXPOSED.
Task-mix shift is genuine here: two tiers exist. If liquid handlers and automated colony counters absorb plating, enumeration and PCR setup, the residual role is contamination root-cause investigation, novel-organism identification where reference databases fail, and experimental design under ambiguity — none of which are template-completable. Watch for QC job postings that drop 'plating/enumeration' and add 'deviation investigation ownership'
FDA guidance on AI in regulated laboratory decision-making (draft 2025 discussion paper on AI in drug/biologic manufacturing) requiring human attestation and documented rationale for any AI-assisted OOS/deviation closure under 21 CFR 211.192
Extension of CLIA-style personal sign-off to non-clinical tiers: FDA's Food Safety Modernization Act preventive-controls rules and USP <1223>/<1071> revisions already name a 'qualified individual' for microbiological method validation; if FDA or a state board required a named, credentialed microbiologist (ASCP/NRCM or equivalent) to personally attest to sterility-release and environmental-monitoring dispositions — as EU Annex 1 effectively does via the Qualified Person for sterile product release — the attestation becomes non-delegable to a software system
Named-investigator requirements in FDA 483/warning-letter remediation and ISO 17025 clause 7.8 revisions that tie an individual, not a team, to result validity and OOS conclusions; also any court treatment of a microbiologist's disposition call as expert opinion in outbreak/product-liability litigation
Growth of biosafety-level-3/4 and field environmental sampling work (wastewater surveillance programs funded via CDC's NWSS, outbreak response) where sampling occurs in unpredictable, non-benchtop environments that automated platforms are not deployed into
The limit. Trust premium has no plausible route: buyers of microbiology are regulators, hospitals and manufacturers who pay for a validated result, not a human one, and nobody in the chain asks the organism's identity to be human-determined. Total realistic ceiling is roughly the high 50s to low 60s — and the liability levers apply mainly to the pharma/food QC tier, not to academic or industrial research microbiologists, who have no comparable route.
| Boston-Cambridge-Newton, MA-NH | 1,810 | $122,350 +39% |
| Washington-Arlington-Alexandria, DC-VA-MD-WV | 1,370 | $114,800 +30% |
| New York-Newark-Jersey City, NY-NJ | 1,330 | $85,710 -3% |
| Chicago-Naperville-Elgin, IL-IN | 1,240 | $100,620 +14% |
| Los Angeles-Long Beach-Anaheim, CA | 780 | $100,420 +14% |
| San Francisco-Oakland-Fremont, CA | 700 | $130,070 +48% |
| Atlanta-Sandy Springs-Roswell, GA | 630 | $109,320 +24% |
| Philadelphia-Camden-Wilmington, PA-NJ-DE-MD | 570 | $101,990 +16% |
| San Francisco-Oakland-Fremont, CA | 700 | $130,070 +48% |
| San Jose-Sunnyvale-Santa Clara, CA | 190 | $123,910 +41% |
| Santa Rosa-Petaluma, CA | 30 | $123,590 +40% |
We have no reported case of a named organisation automating this occupation. Not one deployment, not one announcement.
That is worth saying out loud next to a score of 46. The verdict above is about what the work exposes — what current AI could do to these tasks. It is not a claim that anyone has done it. For this occupation those two things have come apart completely: the capability argument is on this page, and the evidence column is empty.
Has AI actually changed your work? One tap, anonymous, and the running tally is public. Nothing else is asked of you.
Rather than check back: get the digest and we'll tell you what changed — or watch a single occupation from its own page.